Cellectis SA (CMVLF)
OTHER OTC:CMVLF
CMVLF Stock Chart & Stats
$4.40
-$0.25(-16.67%)
At close: 4:00 PM EST
$4.40
-$0.25(-16.67%)
Day’s Range― - ―
52-Week Range$1.25 - $5.04
Previous CloseN/A
Volume1.60K
Average Volume (3M)6.00
Market Cap
$237.08M
Enterprise Value$293.44M
Total Cash (Recent Filing)$208.69M
Total Debt (Recent Filing)$119.91M
Price to Earnings (P/E)―
Beta-0.10
Next Earnings
Apr 30, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding72,325,455
10 Day Avg. Volume20
30 Day Avg. Volume6
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)6.52
Price to Sales (P/S)6.52
P/FCF Ratio-11.22
Enterprise Value/Market Cap1.24
Enterprise Value/Revenue4.02
Enterprise Value/Gross Profit4.80
Enterprise Value/Ebitda-8.60
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.01
Revenue Forecast (FY)$63.43M
Bulls Say, Bears Say
Bulls Say
Proprietary Gene-editing PlatformCellectis' proprietary gene‑editing platform and focus on allogeneic (off‑the‑shelf) CAR‑T creates a structural competitive advantage. A scalable, platform-based approach can lower per‑patient cost, enable multiple programs from shared tech, and attract long-term partner investment.
Strong Gross Margins And Revenue ReboundA sharp revenue rebound coupled with ~72% gross margin indicates the company's core services or partnered programs carry attractive unit economics. High gross profitability provides structural cushion to absorb R&D spend and supports sustainable economics once programs scale or commercialize.
Partner-driven Revenue ModelRevenue derived from collaborations and licensing offers durable non‑product income streams: upfronts, R&D reimbursements and milestones reduce single‑program exposure, can extend runway without immediate product sales, and create long‑term development/commercial links.
Bears Say
Large Persistent Operating And Net LossesSustained large operating and net losses reflect heavy, ongoing R&D and G&A burn. Over time this erodes equity, increases dependence on external financing or dilutive raises, and limits ability to self‑fund pivotal trials or scale commercial capabilities without partners or debt.
Reversal To Negative Cash GenerationA swing from positive to materially negative operating and free cash flow increases near‑term financing pressure. Persistent negative cash generation reduces optionality, raises probability of external funding needs, and can force timing changes to R&D programs or partnership terms.
Rising Leverage And Weakening Balance SheetGrowing debt against declining equity tightens financial flexibility and raises servicing risk. Higher leverage can limit strategic choices, increase cost of capital, and constrain ability to invest in late‑stage development or commercialization, making the company more sensitive to execution setbacks.
Cellectis SA News
CMVLF FAQ
What was Cellectis SA’s price range in the past 12 months?
Cellectis SA lowest stock price was $1.25 and its highest was $5.04 in the past 12 months.
What is Cellectis SA’s market cap?
Cellectis SA’s market cap is $237.08M.
When is Cellectis SA’s upcoming earnings report date?
Cellectis SA’s upcoming earnings report date is Apr 30, 2026 which is in 29 days.
How were Cellectis SA’s earnings last quarter?
Cellectis SA released its earnings results on Mar 19, 2026. The company reported -$0.26 earnings per share for the quarter, missing the consensus estimate of -$0.202 by -$0.058.
Is Cellectis SA overvalued?
According to Wall Street analysts Cellectis SA’s price is currently Overvalued.
Does Cellectis SA pay dividends?
Cellectis SA does not currently pay dividends.
What is Cellectis SA’s EPS estimate?
Cellectis SA’s EPS estimate is -0.26.
How many shares outstanding does Cellectis SA have?
Cellectis SA has 72,325,455 shares outstanding.
What happened to Cellectis SA’s price movement after its last earnings report?
Cellectis SA reported an EPS of -$0.26 in its last earnings report, missing expectations of -$0.202. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cellectis SA?
Currently, no hedge funds are holding shares in CMVLF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cellectis SA
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
CMVLF Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in advancing pivotal clinical trials and maintaining a strong financial position, with ongoing collaborations and upcoming strategic events. However, ongoing arbitration and a decrease in cash reserves posed challenges.View all CMVLF earnings summariesTechnical Analysis
Innate Pharma SA
―
Nanobiotix
―
Transgene
―
OSE Immunotherapeutics SA
―
Sensorion SAS
―
Ownership Overview
―
Insiders
0.02% Other Institutional Investors
99.98% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---